LIVN - Company ID 0001639691
LivaNova PLC trades as LIVN and has a market capitalization of $4.56 B, making it the #1488 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.39B, up 10.7% from the prior year and net income of -$242.50M. This page tracks LivaNova PLC through 917 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years LivaNova PLC's revenue grew from $964.86M to $1.39B, a compound annual growth rate of 4.1%. Net profit margin compressed from -6.5% to -17.5% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| IRANNOTICE | - | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| SCHEDULE 13G/A | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit | LivaNova PLC
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June | LivaNova PLC
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance | LivaNova PLC
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea | LivaNova PLC
LivaNova to Announce First-Quarter 2026 Results | LivaNova PLC
The largest companies sharing LivaNova PLC's SEC industry classification (electromedical & electrotherapeutic apparatus).
LivaNova PLC (LIVN) has a market capitalization of $4.56 B as of 2026-07-09, ranking #1488 among US-listed companies.
LivaNova PLC reported revenue of $1.39B for fiscal year 2025, an increase of 10.7% year over year.
In its latest fiscal year LivaNova PLC reported a net loss of $242.50M.